Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Update on biomarkers in development of anti-angiogenic drugs in gastric cancer

Jia, S. and Cai, Jun 2016. Update on biomarkers in development of anti-angiogenic drugs in gastric cancer. Anticancer Research 36 (3) , pp. 1111-1118.

[thumbnail of 1111.full.pdf]
PDF - Published Version
Download (79kB) | Preview


The treatment of advanced gastric cancer remains challenging as the outcomes achieved with surgery alone or adjuvant or neoadjuvant chemotherapy and radiotherapy are poor. New treatment strategies are emerging and being tested in advanced gastric cancer. Vascular endothelial growth factor (VEGF) inhibitors have been confirmed as important therapeutic agents in randomised clinical trials in multiple solid tumour settings. Until now, results of phase II and phase III clinical trials of anti-angiogenic agents on gastric cancer have been relatively modest, with moderate improvement in overall survival. The effects of these drugs are limited due to development of resistance to them and the increased risk of tumour invasion and metastasis. If we are to optimise or develop combination regimens for advanced gastric cancer with VEGF inhibitors that build on their efficacy, it is critical to identify and validate biomarkers in order to enable selection of those patients who are prone to benefit and monitor their response to the drugs. Validated biomarkers can help to further personalise VEGF inhibitors and dosage determination for advanced or metastatic gastric cancer, particularly as these drugs can be toxic and expensive. Although no biomarker is validated for routine use for this purpose, several candidates are currently under investigation. In this review, we aim to give an overview of the recent developments in biomarkers for anti-angiogenic therapy in gastric cancer tumour angiogenesis.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > R Medicine (General)
Publisher: International Institute of Anticancer Research
ISSN: 0250-7005
Date of First Compliant Deposit: 4 May 2016
Date of Acceptance: 18 February 2016
Last Modified: 18 Jun 2019 10:18

Citation Data

Cited 17 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item


Downloads per month over past year

View more statistics